Biotechnology
Compare Stocks
5 / 10Stock Comparison
NBTX vs ARAY vs ISRG vs NVCR vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Devices
NBTX vs ARAY vs ISRG vs NVCR vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $2.06B | $35M | $161.07B | $1.92B | $99.94B |
| Revenue (TTM) | $48M | $429M | $10.58B | $674M | $35.48B |
| Net Income (TTM) | $-85M | $-46M | $2.98B | $-173M | $4.61B |
| Gross Margin | 100.0% | 26.8% | 66.3% | 75.2% | 61.9% |
| Operating Margin | -143.9% | -5.1% | 30.5% | -27.2% | 17.9% |
| Forward P/E | — | — | 43.8x | — | 14.1x |
| Total Debt | $51M | $176M | $303M | $290M | $28.52B |
| Cash & Equiv. | $50M | $57M | $3.37B | $103M | $2.22B |
NBTX vs ARAY vs ISRG vs NVCR vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Nanobiotix S.A. (NBTX) | 100 | 258.2 | +158.2% |
| Accuray Incorporated (ARAY) | 100 | 7.0 | -93.0% |
| Intuitive Surgical,… (ISRG) | 100 | 166.3 | +66.3% |
| NovoCure Limited (NVCR) | 100 | 9.7 | -90.3% |
| Medtronic plc (MDT) | 100 | 66.6 | -33.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NBTX vs ARAY vs ISRG vs NVCR vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NBTX ranks third and is worth considering specifically for momentum.
- +11.9% vs ARAY's -78.4%
ARAY lags the leaders in this set but could rank higher in a more targeted comparison.
ISRG is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs NBTX's 150.9%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- PEG 2.01 vs MDT's 36.00
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
MDT carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Better valuation composite
- Beta 0.47 vs ARAY's 2.42, lower leverage
- 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs NBTX's -132.1% | |
| Value | Better valuation composite | |
| Quality / Margins | 28.2% margin vs NBTX's -177.5% | |
| Stability / Safety | Beta 0.47 vs ARAY's 2.42, lower leverage | |
| Dividends | 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +11.9% vs ARAY's -78.4% | |
| Efficiency (ROA) | 175.8% ROA vs NBTX's -188.4% |
NBTX vs ARAY vs ISRG vs NVCR vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NBTX vs ARAY vs ISRG vs NVCR vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ARAY leads in 1 of 6 categories
ISRG leads 1 • NBTX leads 1 • NVCR leads 0 • MDT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — NBTX and ISRG each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 740.1x NBTX's $48M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NBTX's -177.5%. On growth, NBTX holds the edge at +186.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $48M | $429M | $10.6B | $674M | $35.5B |
| EBITDAEarnings before interest/tax | -$67M | -$15M | $3.8B | -$165M | $9.4B |
| Net IncomeAfter-tax profit | -$85M | -$46M | $3.0B | -$173M | $4.6B |
| Free Cash FlowCash after capex | -$33M | -$28M | $2.8B | -$48M | $5.4B |
| Gross MarginGross profit ÷ Revenue | +100.0% | +26.8% | +66.3% | +75.2% | +61.9% |
| Operating MarginEBIT ÷ Revenue | -143.9% | -5.1% | +30.5% | -27.2% | +17.9% |
| Net MarginNet income ÷ Revenue | -177.5% | -10.8% | +28.2% | -25.7% | +13.0% |
| FCF MarginFCF ÷ Revenue | -69.2% | -6.5% | +26.8% | -7.1% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +186.8% | -7.4% | +23.0% | +12.3% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +76.1% | -6.1% | +18.8% | -100.0% | -11.9% |
Valuation Metrics
ARAY leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), ISRG offers better value at 2.65x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.1B | $35M | $161.1B | $1.9B | $99.9B |
| Enterprise ValueMkt cap + debt − cash | $2.1B | $154M | $158.0B | $2.1B | $126.2B |
| Trailing P/EPrice ÷ TTM EPS | -25.18x | -18.91x | 57.62x | -13.80x | 21.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 43.84x | — | 14.13x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.65x | — | 36.00x |
| EV / EBITDAEnterprise value multiple | — | 10.99x | 43.62x | — | 14.32x |
| Price / SalesMarket cap ÷ Revenue | — | 0.08x | 16.00x | 2.92x | 2.98x |
| Price / BookPrice ÷ Book value/share | — | 0.37x | 9.17x | 5.51x | 2.08x |
| Price / FCFMarket cap ÷ FCF | — | — | 64.67x | — | 19.28x |
Profitability & Efficiency
ISRG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-77 for ARAY. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ARAY scores 6/9 vs NBTX's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -77.5% | +16.9% | -50.8% | +9.4% |
| ROA (TTM)Return on assets | -188.4% | -10.1% | +14.8% | -16.5% | +175.8% |
| ROICReturn on invested capital | — | +3.0% | +15.0% | -16.4% | +6.0% |
| ROCEReturn on capital employed | -2.6% | +2.8% | +16.5% | -28.9% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 6 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 2.17x | 0.02x | 0.85x | 0.59x |
| Net DebtTotal debt minus cash | $1M | $119M | -$3.1B | $187M | $26.3B |
| Cash & Equiv.Liquid assets | $50M | $57M | $3.4B | $103M | $2.2B |
| Total DebtShort + long-term debt | $51M | $176M | $303M | $290M | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | -3.83x | -1.86x | — | -96.80x | 9.08x |
Total Returns (Dividends Reinvested)
NBTX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NBTX five years ago would be worth $28,294 today (with dividends reinvested), compared to $606 for ARAY. Over the past 12 months, NBTX leads with a +1191.2% total return vs ARAY's -78.4%. The 3-year compound annual growth rate (CAGR) favors NBTX at 99.6% vs ARAY's -56.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +92.5% | -65.5% | -19.3% | +28.3% | -18.1% |
| 1-Year ReturnPast 12 months | +1191.2% | -78.4% | -15.4% | +1.1% | -2.8% |
| 3-Year ReturnCumulative with dividends | +695.0% | -91.8% | +49.6% | -75.7% | -4.2% |
| 5-Year ReturnCumulative with dividends | +182.9% | -93.9% | +58.7% | -91.3% | -27.7% |
| 10-Year ReturnCumulative with dividends | +150.9% | -94.5% | +554.2% | +30.3% | +26.5% |
| CAGR (3Y)Annualised 3-year return | +99.6% | -56.6% | +14.4% | -37.6% | -1.4% |
Risk & Volatility
Evenly matched — NBTX and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NBTX currently trades 95.8% from its 52-week high vs ARAY's 14.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.81x | 2.42x | 1.02x | 2.20x | 0.47x |
| 52-Week HighHighest price in past year | $44.46 | $2.10 | $603.88 | $20.06 | $106.33 |
| 52-Week LowLowest price in past year | $3.26 | $0.28 | $427.84 | $9.82 | $77.16 |
| % of 52W HighCurrent price vs 52-week peak | +95.8% | +14.0% | +75.1% | +83.9% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 68.2 | 58.4 | 42.4 | 69.8 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 75K | 1.4M | 1.8M | 1.5M | 7.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NBTX as "Buy", ISRG as "Buy", NVCR as "Buy", MDT as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -34.3% for NBTX (target: $28). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $28.00 | — | $622.60 | $33.50 | $109.50 |
| # AnalystsCovering analysts | 2 | — | 55 | 15 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.6% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 36 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | 0.0% | +3.2% |
ARAY leads in 1 of 6 categories (Valuation Metrics). ISRG leads in 1 (Profitability & Efficiency). 2 tied.
NBTX vs ARAY vs ISRG vs NVCR vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NBTX or ARAY or ISRG or NVCR or MDT a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -132. 1% for Nanobiotix S. A. (NBTX). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Nanobiotix S. A. (NBTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NBTX or ARAY or ISRG or NVCR or MDT?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Intuitive Surgical, Inc. wins at 2. 01x versus Medtronic plc's 36. 00x.
03Which is the better long-term investment — NBTX or ARAY or ISRG or NVCR or MDT?
Over the past 5 years, Nanobiotix S.
A. (NBTX) delivered a total return of +182. 9%, compared to -93. 9% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus ARAY's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NBTX or ARAY or ISRG or NVCR or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately 419% more volatile than MDT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.
05Which is growing faster — NBTX or ARAY or ISRG or NVCR or MDT?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -132. 1% for Nanobiotix S. A. (NBTX). On earnings-per-share growth, the picture is similar: Accuray Incorporated grew EPS 90. 3% year-over-year, compared to -33. 3% for Nanobiotix S. A.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NBTX or ARAY or ISRG or NVCR or MDT?
Nanobiotix S.
A. (NBTX) is the more profitable company, earning 586. 9% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 586. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBTX leads at 589. 1% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NBTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NBTX or ARAY or ISRG or NVCR or MDT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Intuitive Surgical, Inc. (ISRG) is the more undervalued stock at a PEG of 2. 01x versus Medtronic plc's 36. 00x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 29. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — NBTX or ARAY or ISRG or NVCR or MDT?
In this comparison, MDT (3.
6% yield) pays a dividend. NBTX, ARAY, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.
09Is NBTX or ARAY or ISRG or NVCR or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
47), 3. 6% yield). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NBTX and ARAY and ISRG and NVCR and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NBTX is a small-cap quality compounder stock; ARAY is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while NBTX, ARAY, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.